|
Press Releases
Trillium Strengthens its Board of Directors - November 5, 2008
Click HERE for the full story.
Trillium raises $12 million - September 18, 2008
Click HERE for the full story.
TTI Receives Orphan Drug Status - December 19, 2006
Click HERE for the full story.
Trillium adds late stage preclinical program - April 10, 2006
Click HERE for the full story.
Canada's
Top 10 Investment Prospects Named
- November 7, 2005
Click HERE for
the full story.
Trillium acquires Arthron Ltd. - October 6,
2005
Click HERE for
the full story.
Trillium recognized with national award - May
26, 2005
Click HERE for
the full story.
Trillium and Genentech enter into global
license agreement - December 14, 2004
Click HERE for
the full story.
Professor Marc Feldmann Joins Trillium
Therapeutics' Scientific Advisory Board - June 8, 2004
Click HERE for
the full story.
Trillium Adds Major Cytokine Receptor
Antagonist Program - June 2, 2004
Click HERE for the full story.
Trillium Therapeutics Welcomes Dr. Michael Moore to Board of
Directors - February 23, 2004
Click HERE for the
full story.
Trillium Therapeutics Raises an Additional
$6.0 Million to Close Series A Round at $13.5 Million - February
5, 2004
Click HERE for
the full story.
Trillium Therapeutics and Medarex announce
Collaboration to develop Fully Human Antibody Therapeutics -
October 2, 2003
Click HERE for
the full story.
Trillium Therapeutics Inc. announces
Internationally Renowned Scientists to join New Scientific Advisory
Board - September 12, 2003
Click HERE for
the full story.
Julia Levy and Elizabeth Corsi join
Trillium Therapeutics' Board of Directors - July 15, 2003.
Click HERE for
the full story.
Transplantation Technologies announces
name change to Trillium Therapeutics Inc. and arrival of Dr.
Robert Uger as Director, Research & Development – May
13, 2003.
Click HERE for
the full story.
|